Summary

Global Eczema Therapeutics Market was valued at USD 13.25 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.46% through 2030. The Global Eczema Therapeutics Market refers to the pharmaceutical and healthcare sector dedicated to treating eczema, a chronic skin condition characterized by inflammation, itching, and redness. This market encompasses various products, including topical creams, ointments, oral medications, and biologics, designed to alleviate eczema symptoms and manage the condition. According to the National Eczema Association estimates that 31.6 million Americans have eczema, with cases expected to rise due to pollution, lifestyle changes, and chemical exposure. This growing prevalence is driving demand for effective treatments, fueling the expansion of the eczema therapeutics market. As more people seek relief, pharmaceutical companies are investing in innovative solutions to address this chronic skin condition.
Key Market Drivers
Rising Prevalence of Eczema
The most apparent way in which the rising prevalence of eczema boosts the growth of the eczema therapeutics market is through the expanding patient population. Eczema affects people of all ages, from infants to adults, and its incidence has been steadily climbing. This larger pool of potential patients translates into a growing demand for effective treatments, thereby driving market growth. For instance, according to the National Eczema Association reports that eczema affects over 30 million Americans, with a prevalence of 10%–20% in children and 2%–5% in adults, highlighting its widespread impact and the need for effective treatments across different age groups.
As eczema continues to affect a greater number of individuals and families, awareness of the condition has risen significantly. Patients and their caregivers are increasingly seeking medical advice and treatment options. This growing awareness contributes to early diagnosis and intervention, fostering the adoption of eczema therapeutics and driving market expansion.
Eczema is a chronic condition that can significantly impact a person's quality of life. The constant itching, discomfort, and the potential for skin infections drive individuals to seek solutions that provide relief and long-term management. This demand for effective treatments encourages pharmaceutical companies and researchers to invest in the development of innovative therapies.
Key Market Challenges
Diverse Patient Population
One of the primary challenges faced by the eczema therapeutics market is the diverse nature of the patient population. Eczema can manifest differently in individuals, with varying triggers and severity levels. Tailoring treatments to the specific needs of each patient can be complex and requires a personalized approach. Pharmaceutical companies are increasingly investing in research to address this challenge by developing more targeted therapies.
Key Market Trends
Biologic Therapies Revolutionizing Treatment
Biologic drugs have already made a significant impact on the eczema therapeutics market, but their potential is far from exhausted. In the coming years, we can expect to see the development of more targeted and efficient biologics that offer even better results with fewer side effects. These innovative therapies are likely to become more accessible to a broader range of eczema patients.
Key Market Players
• Sanofi SA
• Encore Dermatology Inc.
• AbbVie Inc.
• F Hoffmann-La Roche AG
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• GSK PLC
• AstraZeneca PLC
• Pfizer Inc.

Report Scope:
In this report, the Global Eczema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Eczema Therapeutics Market, By Treatment:
o Antibiotics
o Antihistamines
o Calcineurin Inhibitors
o Corticosteroids
o Emollients & Moisturizers
o Immunomodulators
o Interleukin Inhibitors
• Eczema Therapeutics Market, By Distribution Channel:
o Hospital & Clinics
o Online Pharmacies
o Retail Pharmacies
• Eczema Therapeutics Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ Germany
§ United Kingdom
§ France
§ Italy
§ Spain
o Asia-Pacific
§ China
§ Japan
§ India
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Eczema Therapeutics Market.
Available Customizations:
Global Eczema Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Eczema Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
5.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
5.3.1. By Treatment
5.3.2. By Distribution Channel
5.3.3. By Region
6. North America Eczema Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
6.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Eczema Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment
6.3.1.2.2. By Distribution Channel
6.3.2. Canada Eczema Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment
6.3.2.2.2. By Distribution Channel
6.3.3. Mexico Eczema Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment
6.3.3.2.2. By Distribution Channel
7. Europe Eczema Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
7.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Eczema Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment
7.3.1.2.2. By Distribution Channel
7.3.2. United Kingdom Eczema Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment
7.3.2.2.2. By Distribution Channel
7.3.3. France Eczema Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment
7.3.3.2.2. By Distribution Channel
7.3.4. Italy Eczema Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment
7.3.4.2.2. By Distribution Channel
7.3.5. Spain Eczema Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment
7.3.5.2.2. By Distribution Channel
8. Asia-Pacific Eczema Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
8.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Eczema Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment
8.3.1.2.2. By Distribution Channel
8.3.2. Japan Eczema Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment
8.3.2.2.2. By Distribution Channel
8.3.3. India Eczema Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment
8.3.3.2.2. By Distribution Channel
8.3.4. Australia Eczema Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment
8.3.4.2.2. By Distribution Channel
8.3.5. South Korea Eczema Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment
8.3.5.2.2. By Distribution Channel
9. South America Eczema Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
9.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Eczema Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment
9.3.1.2.2. By Distribution Channel
9.3.2. Argentina Eczema Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment
9.3.2.2.2. By Distribution Channel
9.3.3. Colombia Eczema Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment
9.3.3.2.2. By Distribution Channel
10. Middle East and Africa Eczema Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
10.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Eczema Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment
10.3.1.2.2. By Distribution Channel
10.3.2. Saudi Arabia Eczema Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment
10.3.2.2.2. By Distribution Channel
10.3.3. UAE Eczema Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment
10.3.3.2.2. By Distribution Channel
10.3.4. Kuwait Eczema Therapeutics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Treatment
10.3.4.2.2. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.6.1. Sanofi SA
14.6.1.1. Business Overview
14.6.1.2. Product Offerings
14.6.1.3. Recent Developments
14.6.1.4. Financials (As Reported)
14.6.1.5. Key Personnel
14.6.1.6. SWOT Analysis
14.6.2. Encore Dermatology Inc
14.6.3. AbbVie Inc
14.6.4. F Hoffmann-La Roche AG
14.6.5. Novartis AG
14.6.6. Regeneron Pharmaceuticals Inc
14.6.7. Astellas Pharma Inc
14.6.8. GSK PLC
14.6.9. AstraZeneca PLC
14.6.10. Pfizer Inc
15. Strategic Recommendations
16. About Us & Disclaimer